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Thousands of potentially antigenic peptides are encoded by an infecting pathogen; however, 
only a small proportion induce measurable CD8
 
 
 
 T cell responses. To investigate the factors 
that control peptide immunogenicity, we have examined the cytotoxic T lymphocyte (CTL) 
response to a previously undefined epitope (
 
77
 
APQPAPENAY
 
86
 
) from the BZLF1 protein of 
Epstein-Barr virus (EBV). This peptide binds well to two human histocompatibility leukocyte 
antigen (HLA) allotypes, HLA-B*3501 and HLA-B*3508, which differ by a single amino acid 
at position 156 (
 
156
 
Leucine vs. 
 
156
 
Arginine, respectively). Surprisingly, only individuals 
expressing HLA-B*3508 show evidence of a CTL response to the 
 
77
 
APQPAPENAY
 
86
 
 epitope 
even though EBV-infected cells expressing HLA-B*3501 process and present similar amounts 
of peptide for CTL recognition, suggesting that factors other than peptide presentation levels 
are influencing immunogenicity. Functional and structural analysis revealed marked 
conformational differences in the peptide, when bound to each HLA-B35 allotype, that 
are dictated by the polymorphic HLA residue 156 and that directly affected T cell receptor 
recognition. These data indicate that the immunogenicity of an antigenic peptide is 
influenced not only by how well the peptide binds to major histocompatibility complex (MHC) 
molecules but also by its bound conformation. It also illustrates a novel mechanism through 
which MHC polymorphism can further diversify the immune response to infecting pathogens.
 
The CD8
 
 
 
 T cell response to an infecting
pathogen is generally focused toward a limited
subset of antigenic peptides presented on the
surface of infected cells. Furthermore, a hierarchy
of immunodominance that is maintained in un-
related individuals is often observed between
those peptides that are the targets of CTL rec-
ognition (1). There appear to be three major
factors that control the immunogenicity of a
foreign peptide: the specificity of the antigen
processing machinery, the peptide binding pref-
erences of MHC class I molecules, and limita-
tions in the diversity of the TCR repertoire (1).
How these parameters focus the CTL response
toward a limited number of determinants within
an antigen is not completely understood.
The dominant factor controlling the magni-
tude of the CTL response to a foreign peptide
is the quantity of peptide presented on the sur-
face of the APC. MHC class I molecules show
strict binding specificity because of the high
level of polymorphism concentrated in the
antigen-binding cleft (2). The pockets (A–F)
of the peptide-binding groove vary in their
depth, electrostatic potential, and hydrophobic-
ity, thereby determining the individual specificity
of the peptide–MHC interaction (3). For most
MHC alleles, two of these pockets display a
marked preference for one or two amino acids,
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termed anchor residues, at certain positions within the pep-
tide. For example, the common class I molecule HLA-
B
 
*
 
3501 prefers peptide ligands, with proline as a dominant
anchor residue at position 2 (P2) and tyrosine (or less com-
monly phenylalanine, methionine, leucine, or isoleucine) at
P
 
 
 
 (the COOH terminus) (4, 5). Peptide amino acids at
other secondary anchor positions can also influence allele-
specific binding (6).
Although immunodominance of antigenic CTL epitopes
usually correlates with the abundance of peptide presented
on the surface of the APC (7), there have been several re-
ports where this is clearly not the case (8, 9). In these in-
stances, the major factors controlling immunodominance
have been proposed to be limitations and bias in the TCR
repertoire imposed by thymic or peripheral selection (1, 10–
12). There has also been a suggestion that some immuno-
dominant determinants may be intrinsically more immu-
nogenic because of an innate propensity to interact with
TCRs, perhaps through the orientation or nature of side
chains available for interaction (1); however, no evidence for
this theory has been presented to date.
We have defined a CTL epitope (
 
77
 
APQPAPENAY
 
86
 
,
referred to as APQP) from the BZLF1 or Z EBV replication
activator protein of EBV that binds well to both HLA-
B
 
*
 
3501 and HLA-B
 
*
 
3508, two closely related molecules
that differ by a single amino acid at position 156 (
 
156
 
Leucine
vs. 
 
156
 
Arginine, respectively). This epitope was found to be
immunogenic in individuals expressing HLA-B
 
*
 
3508 but,
unexpectedly, no response could be detected in HLA-
B
 
*
 
3501
 
 
 
 EBV-exposed individuals, indicating that factors
other than the level of peptide presentation are influencing
immunogenicity. Structural analysis revealed major differ-
ences in the peptide conformation when bound to each
HLA-B35 allotype but, surprisingly, there were no important
differences in the MHC class I heavy chain conformation.
These data indicate that T cell responsiveness to a foreign
peptide can be influenced by its MHC-bound conformation.
 
RESULTS
The influence of a single MHC amino acid difference 
on the immunogenicity of a CTL epitope from BZLF1
 
A highly immunogenic CTL epitope (BZLF1 54–64, EPL-
PQGQLTAY) that binds to HLA-B
 
*
 
3501 has recently been
identified from the BZLF1 antigen of EBV (13, 14). A close
examination of the BZLF1 protein sequence revealed a 10-
mer sequence (BZLF1 77–86, APQPAPENAY) down-
stream from this previously defined 11-mer epitope that also
conforms to the HLA-B35 peptide-binding motif (4, 5). A
peptide corresponding to this 10-mer sequence was tested
for recognition by a CTL line raised from an HLA-B35
 
 
 
EBV-sero
 
 
 
 donor (SB) by in vitro stimulation of PBMCs
with the peptide for 10 d. Our earlier studies have shown
that this stimulation protocol with EBV peptides only in-
duces a measurable in vitro CTL response in donors who
have been previously exposed to the antigenic determinant
through prior infection with EBV, and any peptide-specific
CTL lysis observed in these assays reflects a substantial in
vivo CTL response in these individuals (unpublished data).
This CTL line recognized autologous PHA blasts (SB) only
after pretreatment with the APQP peptide, thereby demon-
strating that this sequence includes an EBV CTL epitope
(Fig. 1 A). To determine if the HLA-B35 allele expressed by
donor SB (HLA-B
 
*
 
3508) is responsible for presenting this
Figure 1. Identification of a CTL epitope from the BZLF1 antigen of 
EBV that is immunogenic in HLA-B*3508  individuals. (A) Cytotoxicity 
by a CTL line raised against the APQP peptide of autologous PHA blast target 
cells (SB) and PHA blasts sharing one HLA allele with the CTLs (underlined). 
The target cells were tested with or without the addition of 0.1  M of the 
APQP peptide. E/T ratio   10:1. (B) Peptide dose-response cytotoxicity assay 
using a CTL line from donor SB (HLA-B*3508 ) raised against the APQP pep-
tide, and PHA blast target cells also from donor SB. E/T ratio   10:1. (C) CTL 
recognition at a variety of E/T ratios by polyclonal T cell lines raised against 
the APQP peptide from PBMCs from eight HLA-B*3501  donors, three 
HLA-B*3501  donors, and one HLA-B*3501/-B*3508 coexpressing donor. 
The target cells were autologous PHA blasts that were pretreated with 
0.1  M of the APQP peptide or left untreated. 
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EBV epitope, cells expressing a range of other HLA alleles
were also included as targets for this CTL line. PHA blasts
sharing HLA-B
 
*
 
3508 with donor SB were recognized effi-
ciently by the CTLs only after the addition of the APQP
peptide, whereas target cells sharing other class I alleles with
donor SB were not lysed, confirming that this peptide is pre-
sented by HLA-B
 
*
 
3508 (Fig. 1 A).
Because the APQP 10-mer peptide includes an 8-mer
sequence that also conforms to the HLA-B35 binding mo-
tif, experiments were conducted to determine the minimal
length of this CTL epitope. All possible 8- and 9-mer pep-
tides from within the APQP 10-mer sequence were tested
for recognition by a CTL line raised from donor SB. This
dose-response experiment clearly shows that the 10-mer
peptide is recognized most efficiently, with high levels of ly-
sis induced with peptide concentrations down to 0.001 
 
 
 
M
(Fig. 1 B), suggesting that APQPAPENAY is the naturally
presented epitope.
To determine if other EBV-sero
 
  
 
HLA-B35
 
 
 
 donors re-
spond to this BZLF1 epitope, CTL lines were raised against
the APQP peptide using PBMCs from a panel of such do-
nors to test for reactivity with the peptide. The donors ex-
pressed either HLA-B
 
*
 
3501 or HLA-B
 
*
 
3508, two allotypes
of the HLA-B35 serotype that diverge by a single amino acid
difference at position 156. Surprisingly, this micropolymor-
phism appeared to have a major impact on responsiveness to
the APQP epitope, because no evidence of a response to the
peptide could be seen with these cytotoxicity assays in any of
eight HLA-B
 
*
 
3501
 
 
 
 donors. In contrast, three donors ex-
pressing the much less common HLA-B
 
*
 
3508 responded
well to the peptide, as did a donor positive for both HLA-
B
 
*
 
3501 and HLA-B
 
*
 
3508 (Fig. 1 C).
 
Peptide conformation, not peptide binding efficiency, 
controls the immunogenicity of a viral CTL epitope
 
To determine if these dramatic differences in responsiveness to
this 10-mer epitope in individuals expressing HLA-B
 
*
 
3501 or
HLA-B
 
*
 
3508 are related to how well the peptide associates
with each HLA-B35 subtype, MHC–peptide binding assays
were conducted. These assays used the T2 cell line transfected
with either HLA-B
 
*
 
3501 or HLA-B
 
*
 
3508. These antigen-
presenting mutant cells express stable class I HLA molecules
on their surface upon addition of exogenous HLA binding
peptide (15). As positive controls for these experiments, pep-
tides known to be highly immunogenic EBV epitopes in
HLA-B
 
*
 
3501
 
 
 
 or HLA-B
 
*
 
3508
 
 
 
 individuals were used for
comparison. These included the BZLF1 11-mer EPLPQGQ-
LTAY (13, 14), which is immunogenic in HLA-B
 
*
 
3501
 
 
 
 in-
dividuals, and the unusually long 13-mer peptide LPEP-
LPQGQLTAY was included for HLA-B
 
*
 
3508 (13, 16). An
earlier study has shown that this 13-mer epitope binds to
HLA-B
 
*
 
3508 more efficiently than the completely overlap-
ping EPLPQGQLTAY 11-mer peptide. Consistent with this
observation, EBV-exposed individuals expressing HLA-B
 
*
 
3508
show a strong CTL response to the 13-mer epitope in prefer-
ence to the overlapping 11-mer peptide (13, 16).
As shown in Fig. 2 A, the APQP peptide stabilized the
expression of both HLA-B
 
*
 
3501 and HLA-B
 
*
 
3508 on the
surface of T2 cells, indicating efficient binding to each class I
molecule. In comparison to the immunogenic 11- or 13-
mer BZLF1 epitopes, the APQP 10-mer bound with similar
efficiency to both HLA-B
 
*
 
3501 and HLA-B
 
*
 
3508.
To investigate the possibility that the APQP peptide may
bind unstably to HLA-B
 
*
 
3501 in comparison to an EBV
epitope that is immunogenic in the context of this class I
molecule, peptide–MHC dissociation rates were examined
on living cells. T2.B
 
*
 
3501 cells were loaded with either
APQP or the highly immunogenic EPLPQGQLTAY pep-
tide and were then washed and assessed for B
 
*
 
3501 surface
expression levels at various time points. The data show that
the two peptides dissociate from HLA-B
 
*
 
3501 at essentially
similar rates (Fig. 2 B), indicating that the contrasting re-
sponses to the APQP epitope in individuals expressing
HLA-B
 
*
 
3501 or HLA-B
 
*
 
3508 is unrelated to peptide–
MHC binding stability.
To determine if the T cells that respond to the APQP
peptide in HLA-B
 
*
 
3508
 
 
 
 donors have the capacity to recog-
nize the peptide bound to HLA-B
 
*
 
3501, peptide-specific
Figure 2. The APQP peptide binds efficiently to both HLA-B*3501 
and HLA-B*3508. (A) Peptide–MHC binding assay comparing APQP with 
other peptides for their ability to stabilize HLA-B*3501 or HLA-B*3508 
expression on T2 cells that had been transfected with these HLA genes. 
These other peptides included EPLPQGQLTAY, an EBV epitope immunogenic in 
HLA-B*3501  individuals (tested only with T2.B*3501), and LPEPLPQGQLTAY, 
an EBV epitope immunogenic in HLA-B*3508  individuals (tested only 
with T2.B*3508). As negative controls, the HLA-A24/-A23–binding 
EBV epitope PYLFWLAAI and a truncated version of the APQP peptide 
(APQPAPENA_) were also included. The T2.B*3501 data were calculated 
relative to the EPLPQGQLTAY peptide used at 100  M, and the T2.B*3508 
data were calculated relative to the LPEPLPQGQLTAY peptide used at 100  M. 
(B) Peptide–MHC dissociation rates were examined for the APQP and the 
EPLPQGQLTAY peptides using T2.B*3501. Data were calculated relative to 
EPLPQGQLTAY at time 0. 
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CTL clones were raised from an HLA-B
 
*
 
3508
 
 
 
 donor and
screened for recognition of the epitope presented on target
cells expressing either HLA-B
 
*
 
3501 or HLA-B
 
*
 
3508 (Fig. 3
A). These peptide dose-response cytotoxicity assays show that
five out of five CTL clones from donor SB recognized the
peptide several orders of magnitude more efficiently in the
context of self–HLA-B
 
*
 
3508 compared with HLA-B
 
*
 
3501,
suggesting that the peptide binds with distinct conformations
on these closely related HLA molecules. To examine this
same issue with a broader range of APQP-specific T cells,
multiple CTL microcultures were generated from donors SB
(HLA-B
 
*
 
3508
 
 
 
) and MB (HLA-B
 
*
 
3501
 
 
 
 and HLA-
B
 
*
 
3508
 
 
 
) by stimulating PBMCs at a limiting dilution with
the APQP peptide. On day 13, the microcultures were
screened for cross-recognition of the peptide presented by ei-
ther HLA-B
 
*
 
3501
 
  or HLA-B*3508  PHA blast target cells
(peptide concentration   0.02  g/ml). The data shown in
Fig. 3 B are from CTL microcultures raised from responder
PBMC densities from which  50% of the wells produced
CTL specific for the EBV epitope; thus, most were likely to
have been generated from a single peptide-specific CTL.
Consistent with data presented in Fig. 3 A, the vast majority
of these CTLs recognized the APQP peptide much more ef-
ficiently when bound to HLA-B*3508  target cells com-
pared with HLA-B*3501  target cells. These data indicate
that the HLA-B*3501–APQP and HLA-B*3508–APQP
structures are quite distinct targets for T cell recognition.
To determine if the APQP peptide is processed and pre-
sented from endogenously expressed viral antigen in HLA-
B*3501  cells, the single T cell microculture from donor SB
(HLA-B*3508 ) that could efficiently cross-recognize the
exogenously added peptide presented by HLA-B*3501 (re-
ferred to as CTL 2D6; Fig. 3 B) was used as a probe for
HLA-B*3501–APQP complexes. Because only a small pro-
portion of cells in lymphoblastoid cell lines (LCLs) express
the BZLF1 lytic antigen of EBV, it was impossible to use
conventional cytotoxicity assays to test for T cell recognition
of endogenously expressed antigen. Instead we used a re-
cently described method (17) that measures IFN-  release in
an ELISPOT assay where the effector T cells were challenged
with LCLs expressing HLA-B*3501 and infected with either
WT EBV (BZLF1  LCLs) or a recombinant EBV in which
the BZLF1 gene was deleted (BZLF1  LCLs). As shown in
Fig. 3 C, the 2D6 CTLs responded strongly to the BZLF1 
LCLs but not the BZLF1  LCLs, demonstrating that the
APQP peptide is processed from endogenously expressed an-
tigen and presented by HLA-B*3501 at sufficient levels for T
cell activation. This data supports the notion that factors
other than peptide presentation levels control the immunoge-
nicity of this viral CTL epitope.
To examine levels of the APQP peptide processed and
presented from endogenously expressed viral antigen in
Figure 3. CTL recognition of the APQP peptide in the context of 
HLA-B*3508 or HLA-B*3501. (A) Peptide dose-response cytotoxicity 
assay using five APQP-specific CTL clones from donor SB (HLA-B*3508 ), 
and PHA blast target cells expressing either HLA-B*3501 or HLA-B*3508. 
E/T ratio   2:1. (B) Multiple CTL microcultures were established from the 
HLA-B*3508  donor SB and the HLA-B*3501/-B*3508 coexpressing donor 
MB by stimulating PBMCs at limiting dilution with the APQP peptide. On 
day 13, the microcultures were screened for cross-recognition of the peptide 
(used at 0.02  g/ml) presented on either HLA-B*3501  or HLA-B*3508  PHA 
blasts. The data are from CTL microcultures raised from responder PBMC 
concentrations from which  50% of the wells produced CTLs specific for 
the stimulator EBV epitope; thus, most were likely to have been generated 
from a single peptide-specific CTL. Data from any CTL microcultures that 
killed the PHA blast target cells without peptide addition was discarded, 
and data are only shown for microcultures that displayed considerable lysis of 
one or both of the peptide-coated target cells. (C) The CTL microculture 2D6 
that could efficiently recognize exogenously added APQP peptide in the 
context of HLA B*3501 was used in an IFN-  ELISPOT assay to determine if 
this epitope is naturally presented on EBV-infected cells expressing this 
HLA allele. The target cells were HLA B*3501  LCLs carrying either the WT 
EBV genome (BZLF1  LCL) or an EBV genome that had been rendered inca-
pable of lytic cycle entry by disruption of the BZLF1 gene (BZLF1  LCL). The 
number of spots per well is shown.JEM VOL. 202, November 7, 2005 1253
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HLA-B*3501  versus HLA-B*3508  cells, we acid eluted
class I–bound peptides from EBV-infected cells expressing
each of these HLA alleles and subjected extracts to HPLC
fractionation. As mentioned in the previous paragraph, only
a small proportion of cells in LCLs express the BZLF1 anti-
gen, which posed a potential problem for these experiments.
Because levels vary slightly between different cell lines, we
used flow cytometry and an mAb for BZLF1 to test several
HLA-B*3501  and HLA-B*3508  LCLs from our stored
panel, and those expressing the highest levels were selected
for further analysis (HLA-B*3501  LCL, 7.3% BZLF1 ;
B*3508  LCL, 3.8% BZLF1 ). Ionizing radiation has been
shown to increase the amount of viral reactivation in LCLs
(18); thus, to ensure that levels of BZLF1 expression were
sufficient for the peptide elution experiments, the LCLs
were  -irradiated (200 rads) and incubated at 37 C over-
night before peptide recovery. This procedure nearly dou-
bled the percentage of cells in our cell lines that were posi-
tive for BZLF1 expression (HLA-B*3501  LCL, 12.3%
BZLF1 ; B*3508  LCL, 6.5% BZLF1 ). Additional control
experiments using ELISPOT assays similar to those shown in
Fig. 3 C showed that processing and presentation of the
APQP peptide were not inhibited by the irradiation step
(unpublished data).
The HPLC fractions from extracts from the two cell lines
that were predicted to include the APQP peptide (based on a
parallel HPLC run with synthetic APQP peptide) were tested
at varying dilutions for recognition by an APQP-specific CTL
clone (Fig. 4, A and B). To allow an estimate of the concentra-
tion of APQP in each fraction, synthetic APQP was tested in
parallel for CTL recognition at varying concentrations (Fig. 4
C). Half-maximum lysis was observed with 48 pg/ml of syn-
thetic peptide (Fig. 4 C), and similar levels of lysis were re-
corded when HLA-B*3501 fraction 32 was used at a dilution
of 1:32 (Fig. 4 A), suggesting that the concentration of APQP
in this fraction was  1,540 pg/ml. Similar extrapolation with
data from the other fractions allowed an estimate of the APQP
concentration in each (Fig. 4 D). The total amount of APQP
peptide eluted off each cell line (from  8   108 cells) was esti-
mated at 90 pg for HLA-B*3501 and 40 pg for B*3508. Be-
cause there were approximately twice as many BZLF1-express-
ing cells in the original HLA-B*3501  population, these data
suggest that similar levels of the APQP peptide are presented
by virus-infected cells expressing these highly homologous
HLA alleles, indicating that other factors must control the im-
munogenicity of this EBV T cell epitope. Further analysis by
liquid chromatography–mass spectrometry of the peptide rep-
ertoire in fraction 32 from the B*3501  LCLs confirmed that
the APQP 10-mer peptide was present (not depicted).
Structural analyses
To determine the effect that the polymorphic residue 156
has on peptide conformation, we determined the structures
of HLA-B*3501 and HLA-B*3508 bound to APQP to 2.0 Å
(Rfactor, 21.3%; Rfree, 23.3%) and 1.8 Å (Rfactor, 20.9%; Rfree,
23.4%), respectively (Table I). These two binary complexes
crystallize in the same space group under identical conditions
with isomorphous unit cells and, importantly, the bound
epitopes do not participate in crystal contacts. Accordingly,
conformational differences that are observed between these
structures can be attributed to the polymorphic amino acid
at position 156. The electron density for the bound peptides
and contacting residues was very clear in the HLA-B*3501-
APQP and the HLA-B*3508-APQP structures (Fig. 5). The
analysis below links changes in peptide conformation to the
local effect of the polymorphism at position 156.
Like the previously determined HLA-B35 structure (19),
the APQP epitope is bound in a slightly bulged mode, with
the N and COOH termini anchored in the A and F pockets,
respectively. 10 out of the 12 direct H bonds between the
peptide and HLA-B*3508 are located within these pockets
(Table II), the majority of which are conserved between all
solved HLA B35 structures (16, 19–21). The P1-C /P -
C  distance in the HLA-B*3508–APQP complex compares
Figure 4. EBV-infected cells expressing HLA-B*3501 or HLA-B*3508 
present similar levels of the APQP peptide after endogenous pro-
cessing. Approximately 8   108 LCLs from the HLA-B3501  donor MW 
or the HLA-B3508  donor CA were irradiated and incubated overnight to 
enhance expression of BZLF1 (donor MW, 12.3% of cells BZLF1 ; donor 
CA, 6.5% of cells BZLF1 ). Cells were then lysed in 0.5% TFA, homogenized, 
and subjected to ultrafiltration and HPLC fractionation. Fractions 30–33 
from (A) the HLA-B*3501  LCL and (B) the HLA-B*3508  LCL that were 
predicted to include the APQP peptide (based on a parallel HPLC run with 
synthetic APQP peptide) were tested at varying dilutions for their ability to 
sensitize HLA-B*3508  target cells to lysis by an APQP-specific CTL clone 
(see panel D for the graph legend; E/T ratio   2:1). The broken lines at the 
points of inflection on the dose-response curves mark the fraction dilution 
that led to 37% lysis. Toxicity controls consisting of target cells incubated 
with fractions in the absence of CTLs were negative (not depicted). (C) To 
allow an estimate of the concentration of the APQP peptide in each fraction, 
synthetic APQP was tested in parallel for CTL recognition at varying con-
centrations. Half-maximum lysis (37%) was measured at a synthetic peptide 
concentration of 48 pg/ml. (D) The concentration of synthetic peptide that 
led to 37% lysis (48 pg/ml) was divided by the fraction dilution that also 
led to 37% lysis to give an estimate of the amount of APQP in each fraction 
and a total amount of the peptide eluted from each cell populations.THE INFLUENCE OF PEPTIDE CONFORMATION ON A CYTOTOXIC T CELL RESPONSE | Tynan et al. 1254
closely with that observed in the previously determined
HLA-B35 complexes (19, 20). The binding pockets for P2-
Pro and P -Tyr, primary anchor residues for HLA-B35, are
conserved between this structure and that previously de-
scribed (20, 21). Positions P4-Pro, P5-Ala, P6-Pro, P8-Asn,
and P9-Ala of the peptide are solvent exposed and thus
represent possible TCR contact points. Interestingly, only
21.4% of the 10-mer is solvent exposed when bound to
HLA-B*3508, compared with 25% for the previously de-
scribed nonameric HLA-B35 complex. This may be attrib-
uted to the apparent secondary anchor residue in the HLA-
B*3508–APQP complex, where the P7-Glu side chain
points down toward the antigen-binding cleft, forming an H
bond with Tyr 74 and salt bridging to Arg 97 and the poly-
morphic Arg 156. This tethering of the central-bulged re-
gion is distinct from several previously determined bulged
peptides where the central bulge participates minimally in
contacts with the antigen-binding cleft (16, 21).
In HLA-B*3508, Arg 156 forms an integral part of an
unusual charged cluster of residues, with its guanadinium
group stacking antiparallel to the guanadinium group of Arg
97. Interestingly, the high-resolution structure has enabled
us to visualize discrete mobility of the Arg 97 and Arg 156
residues, creating two conformations of these residues (Fig. 6
A and Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20050864/DC1). The Arg 97–Arg 156 interaction
is flanked by two salt-bridging residues: Asp 114, a residue
located within the E-pocket, and P7-Glu from the peptide.
The extended conformation of the aliphatic moiety of Arg
156 is further stabilized by van der Waals (v.d.w.) interac-
tions with Leu 126, Trp 133, and Val 152. In one conforma-
tion, Arg 156 also forms a direct H bond with the P3-Gln
(Fig. 6 A). The two conformations of Arg 156 and Arg 97 in
HLA-B*3508 do not affect the conformation of the solvent-
exposed residues of the APQP peptide where no such dis-
crete mobility was observed.
In HLA-B*3501, the positively charged Arg at position
156 is replaced by the hydrophobic Leu residue that forms
v.d.w. contacts with Trp 133, Val 152, and the aliphatic
moiety of Asp 114 and unfavorable v.d.w. interactions with
the charged Arg 97; Leu 156 does not contact the peptide
(Fig. 6 B). To avoid unfavorable interactions with the hy-
drophobic Leu 156, the carboxylate moiety of Asp 114 ro-
tates away to form a more favorable interaction with Arg 97.
Accommodating this polymorphic residue at position 156
requires minimal changes in the HLA-B*3501 heavy chain
(the heavy chains in the two complexes are virtually identi-
cal; C  root mean square deviation   0.25 Å2). However,
the polymorphism at position 156 greatly affects the confor-
mation of the peptide. Somewhat surprisingly, in the HLA-
B*3501–APQP complex, the P7-Glu/Arg 97 salt bridge is
maintained despite the loss of the Arg 156 salt bridge. How-
Figure 5. High resolution structures of HLA-B*3501 and HLA-B*3508 
presenting APQPAPENAY show that the peptides are presented in 
different conformations. Structures of APQP complexed to (A) HLA-B*3508 
and (B) HLA-B*3501. For clarity, the  2 helix has been removed. 2Fo–Fc 
electron density, displayed in mesh format, clearly shows the accurate 
modeling of peptide residues. (C and D) Superposition of the APQP peptides 
presented by HLA-B*3501 (yellow) and HLA-B*3508 (green) show a dramatic 
difference in peptide presentation, including (C) a switch from the P5-Ala 
C  group pointing toward the  1 helix (HLA-B*3508) to the  2 helix 
(HLA-B*3501) and (D) a change from cis–P6-Pro to trans–P6-Pro.JEM VOL. 202, November 7, 2005 1255
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ever, it is the loss of the heavy chain interaction with the P3-
Gln that considerably affects the peptide conformation. This
polymorphism-induced change in peptide interactions cul-
minates in a dramatic shift of residues P4-Pro, P5-Ala, and
P6-Pro of the peptide (Fig. 5, C and D). The side chain of
P3-Gln within the HLA-B*3501–APQP complex swings
upwards, forming H bonds to P5-AlaN and P5-AlaO. To ac-
commodate the new conformation of the P3-Gln, the P4-
Pro is pushed away toward the  1 helix of HLA-B*3501.
The movement of the P4-Pro also includes a dramatic flip in
the main chain carbonyl group P4-Pro peptide main chain,
which then results in a marked shift in the main chain con-
formation of P5-Ala, such that the P5-Ala C  groups are 6.5 Å
apart in the HLA-B*3501 and HLA-B*3508 structures. This
change in peptide conformation also moves the P5-Ala and
P6-Pro closer toward the  2 helix of HLA-B*3501 (Fig. 5
D) and results in a switch from cis–P6-Pro to trans–P6-Pro.
These conformational changes are important enough to
drastically reduce recognition of the HLA-B*3501–APQP
complex by the majority of T cells raised against HLA-
B*3508–APQP.
CTLs specific for the APQP epitope interact with peptide 
residues that are oriented differently when bound to HLA-
B*3501 and HLA-B*3508
To investigate why these peptide structural differences had
such a major impact on CTL recognition, three APQP-spe-
cific CTL clones raised from the HLA-B*3508  donor SB
Table I. Data collection and refinement statistics
Statistics HLA-B*3501 HLA-B*3508
Data collection
Temperature (K) 100 100
Space group P212121 P212121
Cell dimensions
(a,b,c) (Å) 50.81, 81.56, 110.38 50.83, 81.53, 110.73
Resolution (Å) 50–2 50–1.8
Total number of
observations 115,720 158,895
Number of unique
observations 28,293 43,173
Multiplicity 4.1 3.7
Data completeness (%) 88 (82.9) 99.1 (97.7)
Number of data  2 I 72.4 81.7
I/ I 21.4 (3.9) 31.7 (2.82)
Rmerge
a (%) 9.7 (42) 4.3 (49.5)
Refinement
Nonhydrogen atoms
Protein 3160 3185
Water 342 516
Resolution (Å) 2 1.8
Rfactor
b (%) 21.3 20.85
Rfree
b (%) 23.33 23.42
Rms deviations from
ideality
Bond lengths (Å) 0.007 0.005
Bond angles ( ) 1.43 1.24
Impropers ( ) 25.05 24.96
Dihedrals ( ) 0.98 0.88
Ramachandran plot (%)
Most-favored region 90.7 91.8
Allowed region 9.3 8.2
B-factors (Å2)
Average main chain 29.52 27.02
Average side chain 31.86 29.73
Average water molecule 43.04 42.55
Rmsd of bonded Bs 1.76 1.76
aRmerge     | Ihkl     Ihkl   | /  Ihkl.
bRfactor    hkl | | Fo |   | Fc | | /  hkl | Fo | for all data except  4% that were 
used for Rfree calculation.
Figure 6. Local impact of the 156 polymorphism on peptide pre-
sentation. (A) An extensive network of H bonding is seen involving Arg 
156 in HLA-B*3508. Particularly important is the interaction with P3-Gln. 
(B) The polymorphic residue, Leu 156, makes no direct contacts with the 
peptide in HLA-B*3501. The side chain of P3-Gln interacts instead by 
pushing P4-Pro toward the  1 helix and pulling P5-Ala and P6-Pro in 
the direction if the  2 helix. Particularly evident is the switch from 
cis–P6-Pro to trans–P6-Pro. Residues are in ball-and-stick format. Polar 
interactions are depicted as dotted lines. The polymorphic residue is 
green, the peptide is yellow, and other MHC heavy chain residues are 
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were tested for their ability to tolerate single amino acid sub-
stitutions throughout the length of the peptide (Fig. 7,
A–C). To aid with interpretation of this data, peptide–MHC
binding assays were also performed on selected peptides that
were not well recognized by any of the CTL clones. These
binding assays measured stabilization of HLA-B*3508 mole-
cules on the surface of the T2.B*3508 cell line after exoge-
nous peptide addition, and the concentration of peptide re-
quired for half-maximum stabilization of HLA-B*3508 was
then calculated (Fig. 7 D). Considering that the primary an-
chor residues at P2 and P10 were maintained within all the
Table II. APQPAPENAY peptide contacts with HLA-B*3501 
and HLA-B*3508
Peptide
residue MHC residue Type of bond 08/01 
P1
AlaO Tyr 159O  H bond
AlaN Tyr 171O , Tyr 7O  H bond
Ala Met 5, Tyr 7, Tyr 159,
Trp 167, Tyr 171
v.d.w.
 P2
ProO Arg 62N , Arg 62N 2 water mediated 
Pro Tyr 7, Tyr 9, Asn 63,
Phe 67, Tyr 99, Tyr 159
v.d.w.
P3
GlnN Tyr 99O  H bond
GlnO 1 P7 GluO 2 water mediated  01
GlnN 2 P4 ProO water mediated  08
GlnO 1 Arg156N 1 H bond 08(1)
GlnO Asn 70N 2, Tyr 9O , P7 GluO 2 water mediated
Gln Tyr 159, Tyr 99, Ile 66 v.d.w.
Gln Arg 156, Gln 155 v.d.w. 08
P4
Pro Tyr 159 v.d.w.
Pro Ile 66, Leu 163 v.d.w. 01
P5
Ala Ile 66 v.d.w. 08
P6
Pro Thr 69 v.d.w. 08
P7
GluN Asn 70O 1, Thr 73O 1, P7 GluO water mediated 01
GluO Thr73O 1 water mediated 08
GluO 1 Arg 97N 1 salt bridge
GluO 1 Tyr 74O  H bond
GluO 1 P8 AsnO water mediated
GluO 1 Arg 97N 1 water mediated 08
GluO 1 Arg 97N 2 salt bridge 08(2)
GluO 1 Arg 156N 2 salt bridge 08(1)
GluO 2 Arg 97N 2 salt bridge 08(2)
GluO 2 Arg 97N 1 salt bridge
GluO 2 Arg 156N 2, N 1 salt bridge 08(1)
Glu Thr 73, Tyr 74, Asn 70,
Tyr 9, Arg 97
v.d.w.
P8
AsnN Arg 156N 1, N 2 water mediated 08
AsnO Arg 97N 1 water mediated
AsnO Arg 97N 2 water mediated 01
Asn Trp 147, Lys 146, Ala 150 v.d.w.
Asn Val 152 v.d.w. 08
P9
AlaO Trp 147N 1 H bond
Ala Thr 73, Ser 77, Glu 76,
Trp 147, Lys 146
v.d.w.
P 
TyrN Ser 77O  H bond
TyrO Lys 146N , Asn 80O 1 H bond
TyrOXT Thr 143O 1, Tyr 84O  H bond
TyrO  Ser 116O  H bond
Tyr Ser 77, Thr 143, Leu 81, Trp 147,
Tyr 74, Tyr 123, Ser 116, Ile 95,
Arg 97, Lys 146, Tyr 84, Asn 80 
v.d.w.
Figure 7. The impact of single amino acid substitutions within the 
APQP peptide on CTL recognition and HLA-B*3508 binding. The 
APQP-specific CTL clones SB8 (A), SB16 (B), and SB12 (C) were tested for 
recognition of a panel of altered peptide ligands into which single amino 
acid substitutions were introduced (E/T ratio   2:1). A range of peptide 
concentrations were used in these chromium release assays, and the con-
centration required for half-maximum lysis was calculated from this dose-
response data. (D) MHC–peptide binding assays were also conducted by 
testing each peptide at a range of concentrations for its ability to stabilize 
HLA-B*3508 expression on the surface of the antigen-processing mutant 
T2 cell line. The concentration of peptide required for half-maximum 
HLA-B*3508 stabilization was calculated. Peptides that were well recognized 
by a CTL clone were not tested (NT) for MHC binding.JEM VOL. 202, November 7, 2005 1257
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analogues, a surprising number of amino acid substitutions at
other positions within the peptide reduced binding to HLA-
B*3508. Consistent with the structural analysis, the glutamate
at P7 appears to be a particularly important secondary anchor
residue for this peptide because most substitutions at this po-
sition resulted in reduced MHC binding.
A total of 48 analogues of the 10-mer peptide were
tested for CTL recognition over a range of concentrations
using chromium release assays, and the concentration of
peptide required for half-maximum lysis was calculated (Fig.
7, A–C). Each CTL clone displayed a unique pattern of fine
specificity for the 48 analogues, indicating that each ex-
presses a different TCR. CTL recognition by the SB8 CTL
clone was particularly affected by amino acid replacements
toward the COOH terminus of the peptide (Fig. 7 A),
whereas the SB16 clone was focused toward central residues,
with recognition less affected by substitutions at the extrem-
ities of the peptide (Fig. 7 B). The SB12 CTL clone was par-
ticularly tolerant of substitutions toward the COOH termi-
nus, suggesting that the highly exposed peptide residues at
P8 and P9 do not contact the TCR expressed by this clone
(Fig. 7 C). It is notable that all three CTL clones have diffi-
culty recognizing peptides with substitutions at P5 and P6,
suggesting that the alanine and proline residues at these posi-
tions within the EBV peptide might interact closely with the
antigen receptors of these clones. Therefore, these data help
explain why these clones fail to recognize the APQP peptide
bound to B*3501 because the side chains of the residues at
P5 and P6 are oriented quite differently when bound to
B*3501 and B*3508.
DISCUSSION
Polymorphism at the MHC locus enhances immune defense
across the population by ensuring wide variation in the T
cell response to infecting pathogens through presentation of
a broad array of target epitopes (22, 23). This report has
demonstrated another mechanism through which MHC
polymorphism can diversify the immune response to an in-
fecting pathogen. Thus, polymorphic MHC residues can
markedly affect peptide binding conformation as well as
MHC–peptide binding affinity, and this can have a major
impact on the T cell response. Although previous studies
have also demonstrated peptide structural alterations induced
by MHC polymorphism (24, 25), none have shown that
such changes can influence a peptide-specific immune re-
sponse to this extent.
Our data demonstrate that a single residue polymorphism
between HLA-B*3501 and HLA-B*3508 controls respon-
siveness to the APQP epitope through a mechanism unrelated
to peptide–MHC binding efficiency/stability (Fig. 2). Fur-
thermore, HLA-B*3501 , EBV-infected lymphoblasts clearly
present the APQP epitope from endogenously expressed anti-
gen with similar efficiency to HLA-B*3508  LCLs (Fig. 3 C
and Fig. 4), ruling out differences in epitope processing within
EBV-infected cells. It should be noted, however, that the re-
sponse to this epitope could be initiated by cross-priming
through dendritic cells that could process and present a differ-
ent repertoire of EBV peptides compared with infected B
cells. Nonetheless, direct stimulation by EBV-infected B cells
is likely to have the major role in restimulating and maintain-
ing these T cell populations during persistent infection. We
also consider it highly unlikely that polymorphic antigen pro-
cessing genes are influencing this response in our study sub-
jects because our HLA-B*3501  donors were all unrelated
and the HLA-B*3508  donors were from two unrelated fam-
ilies from different ethnic groups.
Another factor with the potential to influence the im-
munogenicity of a T cell epitope is immunodomination
whereby the T cell response to an immunodominant deter-
minant suppresses the response to another epitope (26, 27).
It was therefore feasible that HLA-B*3501, but not HLA-
B*3508, presents another unknown EBV epitope that is
highly immunogenic, thereby suppressing the response to
APQP in HLA-B*3501  individuals. Arguing against this
possibility are data presented in Fig. 1 C and Fig. 3 B show-
ing that the HLA-B*3501/-B*3508–coexpressing donor MB
responds to the APQP epitope.
The potential role of peptide conformation in controlling
the differential responsiveness to this epitope became apparent
after functional assays demonstrated that APQP-specific CTL
clones from an HLA-B*3508  donor were unable to recog-
nize this peptide efficiently in the context of HLA-B*3501
(Fig. 3 A). Thus, although these two closely related HLA
molecules present this identical peptide sequence very effi-
ciently, they appear to be structurally distinct from the per-
spective of many T cells. This conclusion was strengthened by
our analysis of multiple CTL microcultures, most of which
recognized the peptide much more efficiently when presented
on HLA-B*3508  target cells compared with HLA-B*3501 
targets. It is notable that one of the donors used for this analy-
sis coexpressed HLA-B*3501 and HLA-B*3508, yet there
was no indication that T cells had been selected for the ability
to cross-recognize the peptide on each of these HLA mole-
cules (Fig. 3 B). Subsequent structural analysis confirmed ma-
jor conformational differences between the peptide bound to
HLA-B*3501 and HLA-B*3508 resulting from direct peptide
interactions with the polymorphic MHC residue (Fig. 5 and
Fig. 6). Furthermore, the conformational differences were
particularly striking at highly exposed peptide residues that
were shown to be important TCR contact residues for three
out of three APQP-specific CTL clones (Fig. 7).
There are several possible mechanisms through which
such peptide conformational differences could influence im-
munogenicity. It is possible that thymic and postthymic se-
lection influence the relative number of naive T cells with
the capacity to recognize each complex. For example, there
may be an abundantly presented self-peptide that binds to
both HLA-B*3501 and HLA-B*3508 that negatively selects
CTLs with the potential to recognize the HLA-B*3501–
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selects for T cells that recognize the viral peptide presented
by HLA-B*3508 but not HLA-B*3501. Alternatively, cer-
tain self-peptides may be presented preferentially by HLA-
B*3508 that positively select T cells specific for HLA-B*3508–
APQP (11, 12). In any case, the unique conformation of the
APQP peptide when bound to HLA-B*3508 appears to be
critical for recognition by most of the selected T cells and is,
therefore, a major controlling influence over the immunoge-
nicity of this EBV epitope.
Another possible explanation for our data, unrelated to
TCR repertoire differences between HLA-B*3501  and
HLA-B*3508  individuals, is that the conformation of this
EBV epitope on HLA-B*3508 is intrinsically more immu-
nogenic through structural features that enable it to interact
favorably with a higher frequency of TCRs (1). It is now
clear that certain antigenic peptides present challenging tar-
get structures for TCR recognition and are recognized by a
very limited TCR repertoire (16, 28–30). It is therefore not
unreasonable to expect that some peptide conformations will
present docking surfaces complementary to a higher propor-
tion of the TCR repertoire compared with others. Although
it is impossible to decipher the exact mechanisms underlying
the phenomenon, this study clearly demonstrates that pep-
tide conformation can have a dramatic impact on the immu-
nogenicity of an MHC–peptide complex and could there-
fore play a major role in controlling determinant selection
and immunodominance in other T cell responses.
MATERIALS AND METHODS
Cell lines. LCLs were established by exogenous transformation of periph-
eral B cells with EBV and were maintained in growth medium (RPMI
1640 with 10% FCS). The mutant LCL   T lymphoblastoid hybrid cell
line, 174   CEM.T2 (referred to as T2 cells) (31), expressing either HLA-
B*3501 (T2.B*3501) or HLA-B*3508 (T2.B*3508) was also used in this
study and has been described elsewhere (13, 32). PHA blasts were generated
as previously described (10). Blood donors used in this study were healthy
laboratory staff selected for particular HLA alleles and prior exposure to
EBV as assessed by standard virus-specific antibody tests.
CTL cultures. CTL clones were generated by agar cloning as previously
described (10) after initial stimulation of PBMCs for 1 h with 0.1  M of the
APQP peptide. Clones were maintained with biweekly restimulation with
rIL-2 and the  -irradiated (8,000 rads) autologous LCLs that had been
prelabeled with the APQP peptide at 0.1  M for 1 h and washed three
times. Short-term CTL bulk cultures were also used as effectors in cytotox-
icity assays. These were generated by culturing 2   106 PBMCs/2-ml well
in growth medium with autologous PBMCs that had been precoated for
1 h with 0.1  M of the APQP peptide (responder/stimulator   2:1). Cul-
tures were supplemented with 20 U/ml rIL-2 on day 3, split on day 7, and
analyzed on day 10. CTL cultures were tested in duplicate or triplicate for
cytotoxicity in the standard 5-h chromium release assay. In brief, CTLs
were assayed against 51Cr-labeled LCL or PHA blast targets that were pre-
treated with synthetic peptide (Mimotopes Ltd.) or left untreated. The
mean spontaneous lysis for target cells in culture medium was always  20%,
and the variation from the mean specific lysis was  10%.
Short-term CTL microcultures were generated by limiting dilution as
follows: PBMCs were distributed in roundbottom microtiter plates in
growth medium at cell numbers ranging from 103 to 4   104 cells/well.
Approximately 5   104  -irradiated (2,000 rads) autologous PBMCs that
had been preincubated for 1 h with 1  M of the APQP peptide were added
to each well to give a total volume of 100  l. Cultures were fed on days 4,
7, and 10 with 50  l of medium supplemented with 20 U of rIL-2 and 30%
supernatant from MLA-144 cultures. On day 13, each CTL microculture
was split into multiple replicates and used as effectors in a standard 5-h 51Cr-
release assay against target PHA blasts that had been treated with the APQP
peptide or left untreated.
HLA class I peptide binding assays. To assess peptide binding to the
different HLA-B35 subtypes, T2.B*3501 and T2.B*3508 cells were incu-
bated in AIM V serum-free medium (Invitrogen) with various concentra-
tions (0.01, 0.1, 1, 10, and 100  M) of peptides at 26 C for 14–16 h, fol-
lowed by incubation at 37 C for 2–3 h and staining for HLA-B35 surface
expression. To determine peptide dissociation rates, T2.B*3501 cells were
pulsed with 100  M of each peptide at 26 C for 14–16 h, followed by incu-
bation at 37 C for 2–3 h. Cells were then either stained immediately for
HLA-B35 surface expression (0 h) or were washed three times and incubated
at 37 C for 1–6 h before staining. HLA-B35 surface expression was mea-
sured by a flow cytometer (FACSCalibur; Becton Dickinson) using an mAb
to HLA-Bw6 (SFR8 Bw6). Data were expressed relative to the mean fluo-
rescence intensity (MFI) measured using 100  M of a reference peptide that
was known to bind to HLA-B*3501 or HLA-B*3508, using the following
formula: ([MFI with test peptide   MFI without peptide addition]   100) /
(MFI with reference peptide [at 100  M]   MFI without peptide addition).
ELISPOT assays. IFN-  ELISPOT assays were performed using cytokine
capture and detection reagents according to the manufacturer’s instructions
(Mabtech). In brief, anti–IFN-  antibodies were coated on the wells of a 96-
well nitrocellulose plate, and duplicate wells were seeded with 1,000 CD8  T
cells and 50,000 target cells. Two LCLs raised from an HLA B*3501  indi-
vidual were used as target cells in these experiments: one carried a WT B95.8
virus genome (BZLF1  LCL), and the other carried a B95.8 genome that had
been rendered incapable of lytic cycle entry by disruption of the BZLF1 gene
(BZLF1  LCL; a gift from A. Hislop and A. Rickinson, University of Bir-
mingham, UK) (17). After incubation for 16 h, captured IFN-  was detected
with a biotinylated anti–IFN-  antibody followed by development with
streptavidin–horseradish peroxidase complex and chromogenic substrate, and
spots were counted using an automated plate counter (AID).
Expression, purification, and crystallization of HLA-B35 alleles
with APQPAPENAY. Soluble HLA-B*3501 and HLA-B*3508 mole-
cules (residues 1–276) and full-length  2-microglobulin (residues 1–99)
were expressed, refolded with the APQP peptide, purified, and concen-
trated to 10 mg/ml as previously described (33). Crystals were obtained by
the hanging drop vapor diffusion technique. Block-shaped crystals grew
within 4 d in a condition containing 0.2 M ammonium acetate and 16%
wt/vol PEG 3350 (100 mM cacodylate, pH 7.6) at 4 C.
X-ray data collection and structure determination. Crystals were soaked
in reservoir solution containing increasing increments of glycerol as a cryo-
protectant (5, 10, and 15%) and then flash frozen before data collection.
Data were collected on an in-house radiation source and was processed and
scaled using the HKL suite (34).
The HLA-B35 complex structures were refined from an HLA-B*3501
structure that was previously determined in our laboratory (unpublished data).
The model was manually built using the program “O” (35) and improved
through multiple rounds of refinement using the CNS suite (36). The progress
of refinement was monitored by Rfactor and Rfree values. Rigid-body refinement
and simulated annealing were used in the first instance, but in later rounds en-
ergy minimization and B-individual refinement were used to improve the
quality of the model. See Table I for the final refinement and model statistics.
The structures have been deposited in the Protein Data Bank under accession
no. 2AXF (HLA-B*3508–APQP) and 2AXG (HLA-B*3501–APQP).
Purification of HLA complexes and peptide analysis. Purification of
HLA molecules was performed from  8   108 HLA-B*3501  LCLs (do-JEM VOL. 202, November 7, 2005 1259
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nor MW: HLA A1, A3, B8, and B*3501) and HLA-B*3508  LCLs (donor
CA: HLA A30, A32, B42, and B*3508) that had been irradiated (200 rads)
and incubated at 37 C overnight to enhance BZLF1 expression (18). These
LCLs were selected for these experiments on the basis of relatively high lev-
els of BZLF1 expression as measured using flow cytometry and a mouse
mAb to BZLF1 (BZ.1). Peptides were recovered from cell lysates after
treatment with 0.5% TFA and acid extraction from the cell pellet as de-
scribed elsewhere (37). After ultrafiltration (3-kD cutoff) and preconcentra-
tion, peptides were collected in 50- l fractions as described previously (38).
Peptides were separated by RP-HPLC using a SMART system HPLC (GE
Healthcare) with a vydac C18 column (1 mm [inside diameter]   25 cm)
and eluted using an optimized linear gradient of acetonitrile in aqueous
0.09% TFA. Peptide fractions were used in chromium release assays to sen-
sitize HLA-B*3508  LCL target cells for lysis by a CTL clone from the
B*3508  donor SB. In brief, 5  l of each undiluted or diluted fraction was
added to 15  l of target cells for 90 min before CTL addition. To test for
toxicity, each fraction was also added to chromium-labeled target cells
without CTL addition, but no toxicity was detected, even at the lowest di-
lution (1:4; unpublished data). HLA-B*3501 fraction 32 was also character-
ized by liquid chromatography–mass spectrometry using an Ultra ion trap
mass spectrometer coupled to an 1100 nanoLC (both Agilent Technologies)
as described previously (38, 39) and found to contain the APQP 10-mer
peptide after MS/MS fragmentation of the [M 2H]2  species of target mass
m/z   529.2 D (unpublished data).
Online supplemental material. Fig. S1 shows an alternate conformation
of the polymorphic residue 156 in the HLA-B*3508–APQP complex. On-
line supplemental material is available at http://www.jem.org/cgi/content/
full/jem.20050864/DC1.
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